PARIS – October 24, 2025 Sanofi reported a 7.0% sales increase at constant exchange rates (CER) for Q3 2025, supported by strong performance in Dupixent, new product launches like ALTUVIIIO and Ayvakit, and robust R&D productivity. The company posted €12.4 billion in quarterly sales and a 13.2% rise in business earnings per share (EPS), reaffirming its 2025 growth guidance. Two major regulatory approvals — Wayrilz for immune thrombocytopenia in the U.S. and Tzield for delaying stage 3 type 1 diabetes in China — underscored Sanofi’s strategic focus on science, patients, and pipeline execution.
Science Significance
Sanofi’s R&D investment of €1.8 billion this quarter underscores its commitment to scientific advancement. Key achievements include positive phase 3 results for amlitelimab in atopic dermatitis and eight regulatory submission acceptances. The company’s 94-project pipeline spans immunology, rare diseases, neurology, oncology, and vaccines, with several candidates — including SAR446268 (gene therapy for DM1) and SAR402663 (gene therapy for wet AMD) — receiving FDA fast-track designations, marking major progress in next-generation biotherapeutics.
Regulatory Significance
The quarter brought two FDA approvals and three new designations. Wayrilz, a Bruton’s tyrosine kinase inhibitor, gained approval for chronic immune thrombocytopenia, while Tzield earned Chinese NMPA approval for delaying type 1 diabetes onset. Multiple filings, such as Dupixent for chronic spontaneous urticaria in children and Sarclisa subcutaneous formulations, reinforce Sanofi’s regulatory momentum. These milestones highlight compliance excellence and alignment with global health authority standards, demonstrating confidence in the company’s cGxP and clinical governance practices.
Business Significance
Advertisement
With a €2.91 EPS and €2.99 billion in free cash flow, Sanofi sustained profitability while expanding innovation. The acquisition of Vigil Neuroscience and an additional $625 million commitment to Sanofi Ventures strengthened its neuro-immunology pipeline and external innovation ecosystem. The company’s Dupixent franchise crossed €4 billion in quarterly sales, marking a historic first, while newly launched products grew by 57% to reach €1 billion. Sanofi also reaffirmed its €5 billion share buyback program, signaling financial confidence and strategic reinvestment in growth.
Patients’ Significance
Sanofi’s latest launches directly benefit patients with rare diseases, autoimmune disorders, and chronic inflammatory conditions. Therapies like Wayrilz for immune thrombocytopenia and Tzield for type 1 diabetes prevention reflect a shift toward disease-modifying treatments and earlier intervention. Additionally, Sanofi’s Global Health Unit has reached one million patients in 40 low- and middle-income countries, expanding access to essential medicines for non-communicable diseases — a testament to the company’s commitment to equitable healthcare access.
Policy Significance
Sanofi’s expansion of the Insulins Valyou Savings Program in the U.S., effective January 2026, ensures affordable insulin access for all patients, regardless of insurance status, at a fixed $35 monthly cost. The company also joined the Resilient Cities, Reimagining Health coalition, aligning its sustainability goals with global public-health and climate-resilience initiatives. Its formal adoption of the Taskforce on Nature-related Financial Disclosures (TNFD) framework further integrates environmental responsibility into corporate policy.
Sanofi’s Q3 2025 performance exemplifies balanced growth driven by scientific innovation, regulatory success, and sustainability leadership. With strong commercial execution, a robust late-stage pipeline, and continued patient-centric initiatives, the company remains on track for double-digit earnings growth in 2025 and sustained momentum into 2026. Sanofi’s integrated strategy — uniting science, access, and accountability — reinforces its position as a global leader in Bio-Pharma innovation.
Source: Sanofi press release
